Cost-effectiveness of omalizumab in severe persistent asthma in Spain: A real-life perspective

Journal of Asthma

Volumn 52, Issue 2, 2015, Pages 205-210

  Levy, Alberto Nahon ^a   García A Ruiz, Antonio J ^b   García Agua Soler, Nuria ^b   Sanjuan, María Victoria Hidalgo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b UNIVERSIDAD DE MÁLAGA   (Spain)

Author keywords

Asthma; Cost utility; Effectiveness; Healthcare costs; Omalizumab

Indexed keywords

OMALIZUMAB; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SEVERE PERSISTENT ASTHMA; SPAIN; AGED; ASTHMA; COST BENEFIT ANALYSIS; ECONOMICS; EMERGENCY HEALTH SERVICE; LUNG FUNCTION TEST; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; COST-BENEFIT ANALYSIS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 84931091830     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2014.941474     Document Type: Review

References (36)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention [Online]. 2012 Dec (update). Available from: http://www.ginasthma.org/local/uploads/files/GINA-Report-March13.pdf [last accessed Sep 2013].
2. Martínez-Moratalla J, Almar E, Sunyer J, Ramos J, Pereira A, Payo F. European asthma study. Identifying and treating young adults with epidemiological criteria for asthma in five areas of Spain. Spanish Group of the European Asthma Study. Arch Bronconeumol 1999;35:223-228.
3. García-Marcos L, Quirós AB, Hernández GG, Guillén-Grima F, Díaz CG, Ureña IC, et al. Stabilization of asthma prevalence among adolescents and increase among schoolchildren (ISAAC phases I and III) in Spain. Allergy 2004;59:1301-1307.
4. The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Resp J 2003;22:470-477.
5. Xolair. Ficha Técnica del medicamento. The European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Propietary Medicinal Products (CPMP). European Public Assesment Report (EPAR): Xolair. Available from: http:// www.ema.europa.eu. Last Accessed January 2014.
6. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial. Ann Intern Med 2011;154:573-582.
7. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-190.
8. Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma 2012;49:144-152.
9. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-316.
10. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-308.
11. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bouquet J, et al. Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-638.
12. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91:154-159.
13. Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: The 'real-world' effectiveness of omalizumab in allergic asthma. Respir Med 2013;107:1141-1151.
14. Barnes N, Menzies-Gow A, Mansur AH, Spencer D, Percival F, Radwan A, Niven R. Effectiveness of omalizumab in severe allergic asthma: A retrospective UK real-world study. J Asthma 2013;50: 529-536.
15. Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, Rottbauer W, et al. Omalizumab in patients with severe asthma: The XCLUSIVE study. Clin Respir J 2012;6:215-227.
16. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009;103:1633-1642.
17. Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009;103:1725-1731.
18. Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, Caiaffa MF, et al. Italian real-life experience of omalizumab. Respir Med. 2010;104:1410-1416.
19. Korn S, Schumann C, Kropf C, Stoiber K, Thielen A, Taube C, Buhl R. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol. 2010;105:313-319.
20. Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, Molimard M, et al. Pharmacoepidemiology of Asthma and Xolair (PAX) Study Group. Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma. Chest 2013;143:398-405.
21. López Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, Puig-Junoy J. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit 2010; 24:154-170.
22. Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma 2012;49:843-848.
23. National Institute for Health and Clinical Excellence (NICE). Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201) [Online]. 2013 Apr. Available at: http://www.nice.org.uk/nicemedia/live/14157/63689/ 63689.pdf. [last accessed Sep 2013].
24. Dewilde S, Turk F, Tambour M, Sandström T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:1765-1776.
25. Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Costeffectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007:120: 1146-1152.
26. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32-38.
27. Comité Ejecutivo GEMA 2009. Guía española del manejo del asma. Arch Bronconeumol 2009:45:2-35.
28. Dilla T, González de Dios J, Sacristán JA. Evaluación Económica en Medicina (I): fundamentos y Metodología. Evid Pediatr 2009;5:71.
29. Chen H, Gould MK, Blanc PD, Miller DP, Kamath TV, Lee JH, Sullivan SD. TENOR Study Group. Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease. J Allergy Clin Immunol 2007;120:396-402.
30. CGCOF. Consejo General del Colegio Oficial de Farmacéuticos. Base de datos del medicamento [Online]. 2012. Available from: http://www.portalfarma.com [last accessed Dec 2012].
31. R Core Team. 2013. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
32. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002;16: 334-343.
33. van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ 2013;16:342-348.
34. Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011;43:45-53.
35. Watson L, Turk F, James P, Holgate ST. Factors associated with mortality after an asthma admission: A national United Kingdom database analysis. Respir Med 2007;101:1659-1664.
36. Löwhagen O, Ekström L, Holmberg S, Wennerblom B, Rosenfeldt M. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997;35:243-247.